Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

Truist has raised its price target for BridgeBio Pharma, Inc. (BBIO) to $95, reiterating a Buy rating for the pharmaceutical company.